ACET
Adicet Bio, Inc. (NASDAQ)
Healthcare — Biotechnology
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
None
6 analysts
$8.59
$-0.02 (-0.58%)
Target:
$34.83
(305.5%)
Sign in to add ACET to a watchlist or set price alerts.
Price History
Fundamentals
| Market Cap | $80.02M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.04 |
| EPS (TTM) | $-13.87 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $34.83 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 71.8 |
| Beta | 1.59 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | - |
| 52-Week Low | - |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | - |
Performance Analysis
NEUTRALACET presents a mixed picture with both positive and negative indicators.
-
RSI at 71.8 indicates overbought conditions — a pullback may be due.
~
Wall Street consensus is "none" from 6 analysts.
+
Average analyst target of $34.83 implies 305.5% upside.
Recent News
Loading news...
Last updated: Jul 01, 2026 15:01 UTC
Back to Screener Export Report